FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143131617> ?p ?o ?g. }

• W2143131617 endingPage "1467" @default.
• W2143131617 startingPage "1464" @default.
• W2143131617 abstract "<h3>Background</h3> Overuse tendon injury (tendinopathy) occurs in loaded tendons of the upper and lower limb and results in pain, decreased exercise tolerance of the tendon and a reduction in function. Characteristic changes occur in tendon structure, resulting in a tendon that is less capable of sustaining repeated tensile load. <h3>Objectives</h3> The aim of this study was to evaluate the efficacy and safety of a food supplement containing mucopolysaccharides, collagen type I and vitamin C on the clinical symptoms, pain and tendon structure of patients with tendinopathy of Achilles, supraspinatus, lateral epicondyle or plantar fasciitis. <h3>Methods</h3> Patients with clinically and sonographically diagnosed tendinopathy were randomized to receive two capsules per day of Tendoactive® (TA) (435mg of mucopolysaccharides, 75mg of collagen type I and 60mg of vitamin C) or two identical capsules of placebo (PBO) during 90 days. An oral NSAID (Mobic® 7.5 mg/day) was allowed in both groups as rescue medication for a maximum of 30 days. Patients were monitored monthly during the study period. Clinical assessments included presence/absence of clinical symptoms (swelling, burn and redness) and pain intensity using a visual analog scale (VAS). Tendon structure was characterized sonographically and presence/absence of tendinopathy was reported. <h3>Results</h3> A total of 60 patients were included, 30 assigned to each treatment group. Average age was 41,4±1,50 years in TA group and 40,2±0,26 years in PBO group. They were mostly women in both groups (83.3% and 86% in TA and PBO groups respectively). The percentage of patients presenting each clinical symptom was progressively reduced in both groups, reaching lower values in the TA group at each time point. Pain level assessed by VAS was comparable between groups at baseline (5,82±0,21 vs 5,71±0,23 in TA and PBO groups respectively). It was significantly reduced in both groups during the study period, but patients supplemented with TA had significantly lower pain value at 90 days (2,5±0,22 vs 3,20±0,20 in TA and PBO groups respectively; P<0.05). At the end of study, no patient in the TA group was diagnosed for tendinopathy according to ultrasounds assessment. <h3>Conclusions</h3> The overall results of this randomized, placebo-controlled study show that Tendoactive® supplementation is a safe and effective therapeutic option to improve both clinical symptoms and structural evolution of injured tendons as demonstrated in Achilles, supraspinatus, lateral elbow epicondyle and plantar fasciitis. <h3>References</h3> F. Nadal, T. Bové, D. Sanchís, D. Martinez-Puig. Effectiveness of treatment of tendinitis and plantar fasciitis by Tendoactive. Osteoarthritis and Cartilage 2009;17(1):S253 M. Shakibaei, C. Buhrmann and A. Mobasheri. Anti-inflammatory and anti-catabolic effects of TENDOACTIVE® on human tenocytes in vitro. Histology and Histopathology 2011;26:1173-1185 <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5477" @default.
• W2143131617 created "2016-06-24" @default.
• W2143131617 creator A5009737732 @default.
• W2143131617 creator A5034534157 @default.
• W2143131617 creator A5045937070 @default.
• W2143131617 creator A5062695079 @default.
• W2143131617 creator A5086061775 @default.
• W2143131617 date "1994-10-01" @default.
• W2143131617 modified "2023-10-16" @default.
• W2143131617 title "Common bile duct stones are mainly brown and associated with duodenal diverticula." @default.
• W2143131617 cites W146332778 @default.
• W2143131617 cites W1718023142 @default.
• W2143131617 cites W1925750164 @default.
• W2143131617 cites W1969039489 @default.
• W2143131617 cites W1973778714 @default.
• W2143131617 cites W1974930475 @default.
• W2143131617 cites W1976901296 @default.
• W2143131617 cites W1987352855 @default.
• W2143131617 cites W1987435745 @default.
• W2143131617 cites W1987922390 @default.
• W2143131617 cites W1988872823 @default.
• W2143131617 cites W1996848397 @default.
• W2143131617 cites W2009196967 @default.
• W2143131617 cites W2021165363 @default.
• W2143131617 cites W2022232907 @default.
• W2143131617 cites W2026981471 @default.
• W2143131617 cites W2044474271 @default.
• W2143131617 cites W2045849042 @default.
• W2143131617 cites W2046413299 @default.
• W2143131617 cites W2049496622 @default.
• W2143131617 cites W2081526298 @default.
• W2143131617 cites W2103045953 @default.
• W2143131617 cites W2132860204 @default.
• W2143131617 cites W2151913392 @default.
• W2143131617 cites W2161050726 @default.
• W2143131617 cites W2312752376 @default.
• W2143131617 cites W2420057994 @default.
• W2143131617 cites W4251788912 @default.
• W2143131617 doi "https://doi.org/10.1136/gut.35.10.1464" @default.
• W2143131617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1375026" @default.
• W2143131617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7959206" @default.
• W2143131617 hasPublicationYear "1994" @default.
• W2143131617 type Work @default.
• W2143131617 sameAs 2143131617 @default.
• W2143131617 citedByCount "40" @default.
• W2143131617 countsByYear W21431316172012 @default.
• W2143131617 countsByYear W21431316172016 @default.
• W2143131617 countsByYear W21431316172018 @default.
• W2143131617 countsByYear W21431316172020 @default.
• W2143131617 countsByYear W21431316172022 @default.
• W2143131617 crossrefType "journal-article" @default.
• W2143131617 hasAuthorship W2143131617A5009737732 @default.
• W2143131617 hasAuthorship W2143131617A5034534157 @default.
• W2143131617 hasAuthorship W2143131617A5045937070 @default.
• W2143131617 hasAuthorship W2143131617A5062695079 @default.
• W2143131617 hasAuthorship W2143131617A5086061775 @default.
• W2143131617 hasBestOaLocation W21431316171 @default.
• W2143131617 hasConcept C126322002 @default.
• W2143131617 hasConcept C141071460 @default.
• W2143131617 hasConcept C14184104 @default.
• W2143131617 hasConcept C142724271 @default.
• W2143131617 hasConcept C204787440 @default.
• W2143131617 hasConcept C27081682 @default.
• W2143131617 hasConcept C2776497992 @default.
• W2143131617 hasConcept C2777069013 @default.
• W2143131617 hasConcept C2778911562 @default.
• W2143131617 hasConcept C2780105995 @default.
• W2143131617 hasConcept C2780984734 @default.
• W2143131617 hasConcept C71924100 @default.
• W2143131617 hasConceptScore W2143131617C126322002 @default.
• W2143131617 hasConceptScore W2143131617C141071460 @default.
• W2143131617 hasConceptScore W2143131617C14184104 @default.
• W2143131617 hasConceptScore W2143131617C142724271 @default.
• W2143131617 hasConceptScore W2143131617C204787440 @default.
• W2143131617 hasConceptScore W2143131617C27081682 @default.
• W2143131617 hasConceptScore W2143131617C2776497992 @default.
• W2143131617 hasConceptScore W2143131617C2777069013 @default.
• W2143131617 hasConceptScore W2143131617C2778911562 @default.
• W2143131617 hasConceptScore W2143131617C2780105995 @default.
• W2143131617 hasConceptScore W2143131617C2780984734 @default.
• W2143131617 hasConceptScore W2143131617C71924100 @default.
• W2143131617 hasIssue "10" @default.
• W2143131617 hasLocation W21431316171 @default.
• W2143131617 hasLocation W21431316172 @default.
• W2143131617 hasLocation W21431316173 @default.
• W2143131617 hasLocation W21431316174 @default.
• W2143131617 hasOpenAccess W2143131617 @default.
• W2143131617 hasPrimaryLocation W21431316171 @default.
• W2143131617 hasRelatedWork W1534277560 @default.
• W2143131617 hasRelatedWork W1969774185 @default.
• W2143131617 hasRelatedWork W2087830556 @default.
• W2143131617 hasRelatedWork W2088334756 @default.
• W2143131617 hasRelatedWork W2092864984 @default.
• W2143131617 hasRelatedWork W2151367930 @default.
• W2143131617 hasRelatedWork W2806566775 @default.
• W2143131617 hasRelatedWork W3182064889 @default.
• W2143131617 hasRelatedWork W4248936431 @default.
• W2143131617 hasRelatedWork W4385707508 @default.

• next